Christopher B. Prentiss - 13 May 2025 Form 4 Insider Report for MANNKIND CORP (MNKD)

Role
Chief Financial Officer
Signature
/s/ Christopher Prentiss
Issuer symbol
MNKD
Transactions as of
13 May 2025
Net transactions value
$0
Form type
4
Filing time
15 May 2025, 20:34:32 UTC
Previous filing
28 Mar 2025
Next filing
17 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Prentiss Christopher B Chief Financial Officer 1 CASPER STREET, DANBURY /s/ Christopher Prentiss 15 May 2025 0001717583

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNKD Common Stock, $0.01 Par Value Award $0 +119,000 +51% $0.000000 353,193 13 May 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNKD Performance Restricted Stock Unit Award $0 +145,000 $0.000000 145,000 13 May 2025 Common Stock, $0.01 Par Value 145,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2 Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F3 The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
F4 Includes 1,593 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024.